A1C change

The primary outcome is the difference in change in A1C calculated from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months

Estimated cardiovascular risk

The primary outcome is the difference in change in estimated CV risk from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Blood Pressure

The difference in change in blood pressure from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

LDL cholesterol concentration

The difference in change in serum LDL-cholesterol concentration from baseline to the end of the study (up to six months) between the intervention and control groups

Up to 6 months.

Influenza vaccination

The difference in the proportion of participants who receive their influenza vaccination from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Pneumococcal vaccination

The difference in the proportion of participants who receive their pneumococcal vaccination from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months

Foot exam

The difference in the proportion of participants who complete foot exams from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months

Eye Exam

The difference in the proportion of participants who complete eye exams from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Renal function screening

The difference in the proportion of participants who complete renal function screening (glomerular filtraion rate, albumin to creatinine ratio) from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Vascular Protection

The difference in the proportion of participants who have guideline-based vascular protection in place from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Pharmacist prescribed prescription medications

Pharmacist prescribing or changing the dose of medications from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Pharmacist provided education on lifestyle factors

Education on lifestyle factors (tobacco cessation, diet, exercise) from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months

Pharmacist provided education on medications and importance of adherence.

Pharmacist intervention of providing education on medications and importance of adherence from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months

Laboratory Monitoring

The difference in the proportion of participants who attend the laboratory for routine monitoring from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Continuous Glucose Monitoring

The difference in the proportion of participants who use continuous glucose monitoring devices from baseline to the end of the study (up to six months) between the intervention and control groups.

Up to 6 months.

Yield of enrolment approaches

The yield from each enrolment approach used (active case-finding approach vs. passive approaches such as when the patient attends the pharmacy to collect a prescription medication or through patient self-identification).

Up to 6 months.

Yield of enrollment by pharmacy type

Yield of enrollment by clinic or non-clinic pharmacy type.

Up to 6 months.

Shared-decision making uptake

Extent to which shared decision making was achieved in the intervention as measured by the validated Shared Decision Making 9-item Questionnaire (SDM-Q-9) tool. The minimum score is 0 and the maximum score is 45, where a higher score indicates a greater subjective level of shared decision making.

Up to 6 months.

Patient satisfaction - standard

Patient satisfaction as measured by the diabetes treatment satisfaction questionnaire standard (DTSQs). The standard version of the DTSQ consists of eight questions on a 0-6 Likert scale (where 0 is very dissatisfied and 6 is very satisfied). Minimum score = 0, maximum score = 48.

Up to 6 months.

Patient satisfaction - change

Patient satisfaction as measured by the diabetes treatment satisfaction questionnaire change (DTSQc). It is designed to overcome ceiling effects, where satisfaction is already high, by allowing for more precise reporting of improvements or declines, and thus must be used alongside the DTSQs to understand both the absolute satisfaction level and the change over time. The change version of the DTSQ consists of eight questions on a 0-6 Likert scale (where 0 is very dissatisfied and 6 is very satisfied). Minimum score = 0, maximum score = 48.

Up to 6 months.